Combined Treatment of RFA and Sorafenib on Recurrent HCC

Southwest Hospital, China430 enrolled

Overview

RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC. So the investigators hypothesized that combined RFA and Sorafenib might reduce the frequency of recurrence and improve the overall survival and disease free survial.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

DOUBLE

Enrollment

430

Conditions

HCC Radiofrequency Ablation Sorafenib

Interventions

RFA + SorafenibOTHER

combined RFA and Sorafenib to treat recurrent HCC

RFAOTHER

treat Recurrent HCC with RFA

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * recurrent HCC after curative resection * without gender restriction * age between 18 to 75 years * The liver function showed no worse than Child-Pugh B * tumor nodes were less than 5cm and no more than 3 nodules Exclusion Criteria: * Pregnancy patients * With extrahepatic tumor or lymphnode metastasis * Tumor invasion or thrombosis in portal vein,hepatic vein or inferior vena cava

Locations (1)

Institute of hepatobiliary surgery,southwest hospital

Chongqing, Chongqing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

time interval between new lessions emerging after the first HCC recurrence

Time frame: 3 year

Secondary Outcomes

3-year overrall survival

Time frame: 3 year

Central Contacts

Xiaobin Feng, MD

CONTACT

+86-2368765297 fengxiaobin200708@aliyun.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.